Human coronary artery thrombi were obtained using a thrombectomy catheter (Export catheter, Medtronic, Minneapolis, MN, USA) during percutaneous coronary intervention prior to balloon angioplasty and stent deployment in AMI patients. The coronary thrombus tissues were obtained by using an aspiration catheter. The expression of S100B and MPO (EPR20257, ABCOM, USA) in the coronary artery thrombus was examined using immunohistochemistry and immunofluorescence staining. S100B and MPO antibodies were incubated overnight at 4°C with thrombus samples; the bound S100B and MPO antibodies were stained using avidin–biotin–peroxidase method (Vector Laboratories, Burlingame, CA, USA) and photographed under a microscope (ZEISS, Image A2, Germany).
Export catheter
Manufactured by Medtronic
Sourced in United States
The Export catheter is a medical device designed for use in a variety of clinical procedures. It is a flexible, tubular instrument that can be inserted into the body to facilitate the movement of fluids or other materials. The core function of the Export catheter is to provide a controlled and safe channel for the transportation of substances within the patient's body. Detailed specifications and intended use are not available in this factual and unbiased description.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using export catheter
1
Assessing Coronary Thrombus Biomarkers
2
Quantitative Analysis of Thrombectomy Outcomes
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The data generated in the current study are available from the corresponding author on reasonable request. The TOTAL trial was a multicenter prospective randomized trial that enrolled 10 732 patients presenting with ST-segment-elevation MI undergoing primary PCI. 1 (link) Patients were randomized to routine manual thrombectomy aspiration with (Export Catheter; Medtronic, Santa Rosa, CA) versus PCI alone. The outcomes of the TOTAL study were reported previously. 1 (link) This study is a single-arm analysis of patients from TOTAL who underwent manual aspiration thrombectomy before PCI in the thrombectomy arm of the study with a recorded run of the thrombectomy catheter available for analysis. This allowed for objective quantification of rTB immediately after the final thrombectomy run. Patients randomized to the PCI-alone group were excluded from the current analysis.
3
Primary PCI with Thrombectomy Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The protocol was approved by the institution ethical board and was performed in accordance with the Declaration of Helsinki. All patients signed written informed consent and pretreated immediately prior revascularization with 300 mg of aspirin, 100 U per kilogram body weight of intravenous heparin, and 300 mg of clopidogrel. Standard primary PCI was performed. Thrombectomy was performed based on operator discretion using Export catheter (Medtronic Inc., Santa Rosa, CA, USA) and Thrombuster catheter (Kaneka Inc., Japan). Aspiration was performed by more than two passages across the lesion. Subsequently, patients received aspirin, clopidogrel (at 12 months), nitrates, beta-blockers, angiotensin-converting enzyme inhibitors, and statins.
4
Aspirin, Clopidogrel, and Heparin in NSTEMI
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Thirty NSTEMI patients received 300mg Aspirin followed by 75mg once daily (OD); 300mg
Clopidogrel followed by 75mg OD and low molecular weight heparin prior to PCI. SA patients were treated with aspirin 75mg OD and clopidogrel 75mg OD for at least 7 days prior to PCI.
Coronary angiography was carried out through trans femoral access. Right atrial blood samples were obtained using a 5F multipurpose catheter (5F, Cordis ®, internal diameter 0.11cm) via the femoral vein. Left and right coronary artery angiography was performed with a 5F Judkin's left 4 and right 4 diagnostic catheters (Cordis ®, internal diameter 0.11cm).
Following diagnostic angiography the culprit lesion was identified and weight adjusted unfractionated heparin was given prior to advancing the guide wire to achieve an activated clotting time (ACT) of 200 and 250 sec. After wiring of the culprit lesion an aspiration catheter (Medtronic ® Export catheter, internal diameter 0.10 cm) was advanced distal to the culprit lesion and 10 millilitres (mls) of blood was aspirated. Catheters with similar internal diameter were used for blood sample collection to minimise shear stress related in vitro platelet activation. PCI was performed according to standard procedures following blood sampling.
Clopidogrel followed by 75mg OD and low molecular weight heparin prior to PCI. SA patients were treated with aspirin 75mg OD and clopidogrel 75mg OD for at least 7 days prior to PCI.
Coronary angiography was carried out through trans femoral access. Right atrial blood samples were obtained using a 5F multipurpose catheter (5F, Cordis ®, internal diameter 0.11cm) via the femoral vein. Left and right coronary artery angiography was performed with a 5F Judkin's left 4 and right 4 diagnostic catheters (Cordis ®, internal diameter 0.11cm).
Following diagnostic angiography the culprit lesion was identified and weight adjusted unfractionated heparin was given prior to advancing the guide wire to achieve an activated clotting time (ACT) of 200 and 250 sec. After wiring of the culprit lesion an aspiration catheter (Medtronic ® Export catheter, internal diameter 0.10 cm) was advanced distal to the culprit lesion and 10 millilitres (mls) of blood was aspirated. Catheters with similar internal diameter were used for blood sample collection to minimise shear stress related in vitro platelet activation. PCI was performed according to standard procedures following blood sampling.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!